{"id":"NCT01072331","sponsor":"Mitsubishi Tanabe Pharma Corporation","briefTitle":"Pharmacokinetic/Pharmacodynamic Study of MP-513 With Type 2 Diabetes Mellitus","officialTitle":"Pharmacokinetic/Pharmacodynamic Study of MP-513 in Japanese Patients With Type 2 Diabetes Mellitus","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-02","primaryCompletion":"2010-08","completion":"2010-08","firstPosted":"2010-02-22","resultsPosted":"2012-12-19","lastUpdate":"2013-04-09"},"enrollment":99,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Type 2 Diabetes Mellitus"],"interventions":[{"type":"DRUG","name":"MP-513","otherNames":[]},{"type":"DRUG","name":"MP-513","otherNames":[]},{"type":"DRUG","name":"Placebo of MP-513","otherNames":[]}],"arms":[{"label":"MP-513 10 mg, once a day, for 4 weeks","type":"EXPERIMENTAL"},{"label":"MP-513 20 mg, once a day, for 4 weeks","type":"EXPERIMENTAL"},{"label":"Placebo of MP-513","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to evaluate the effect of MP-513 on 24-h glycemic control in patients with type 2 Diabetes for 4 weeks administration.","primaryOutcome":{"measure":"Change From Baseline in 2-h Postprandial Glucose (Breakfast, Lunch and Dinner)","timeFrame":"4 weeks","effectByArm":[{"arm":"MP-513 10 mg","deltaMin":-56.2,"sd":5.5},{"arm":"MP-513 20 mg","deltaMin":-43.7,"sd":5.8},{"arm":"Placebo of MP-513","deltaMin":-5.5,"sd":6}],"pValues":[]},"eligibility":{"minAge":"20 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":6},"locations":{"siteCount":1,"countries":["Japan"]},"refs":{"pmids":["22776014"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":34},"commonTop":["Nasopharyngitis","Glucose urine present","Upper respiratory tract inflammation","Protein urine present","Blood triglycerides increased"]}}